GLP-1 & Metabolic Peptides
Survodutide (BI 456906)
Commonly used for
Weight LossFatty Liver SupportMetabolic Health
What is it?
Survodutide is a dual GLP-1/glucagon receptor agonist that combines appetite suppression with increased energy expenditure.
Mechanism of action: GLP-1 receptor agonist; Glucagon receptor agonist; Promotes satiety; Increases fat oxidation; Raises energy expenditure
What do people use it for?
Proposed indications: Obesity; MASH; Fatty liver disease; Type 2 diabetes
How is it used? / Dosing
Reported dosing range*: 0.6, 2.4, 3.6, or 4.8 mg once weekly, subcutaneous
The Phase 2 obesity dose-finding trial randomized participants to once-weekly subcutaneous doses of 0.6, 2.4, 3.6, or 4.8 mg for 46 weeks (le Roux CW et al. (2024). Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity: A Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Trial. The Lancet Diabetes & Endocrinology).
*General range reported in available research or other sources -- not an individualized recommendation. Actual use should be supervised by a qualified provider.
Typical clinical dosing schedule: Weekly dose escalation in clinical trials. No approved dosing schedule exists.
Administration: Subcutaneous injection — Weekly
How does it compare?
Compare with:
How well does it work? / Evidence
~ Moderate evidence
Evidence rating: ⭐⭐⭐⭐☆ — Phase 2 studies demonstrated clinically meaningful weight loss and improvements in liver fat and fibrosis markers.
Landmark trials: Phase 2 dose-finding obesity trial (2024) — Randomized, double-blind, placebo-controlled trial of weekly survodutide in adults with overweight or obesity; published in Lancet Diabetes & Endocrinology.
Safety & side effects
Common side effects: Nausea, Vomiting, Diarrhea, Constipation
Serious risks: Long-term safety is still under investigation.
Monitoring: Weight, Liver enzymes, HbA1c, GI symptoms
Legal & regulatory status
Legal status: Investigational. Not FDA-approved and not available by prescription — currently accessible only through enrollment in a clinical trial.
Regulatory status: Phase 3 • Not FDA Approved
Who should avoid it?
Contraindications: Not established. Clinical trials excluded patients with:; Severe liver disease unrelated to MASH; Pregnancy; MEN2/MTC risk factors
Pregnancy & breastfeeding: Avoid.
Research & references
le Roux CW et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. EASL Congress presentations on Survodutide in MASH.